These data therefore indicate that HMGB1 signalling plays a minor role in the SOD1G93A model of ALS, limiting the further exploration of targeted HMGB1 inhibition with antibodies such as 2G7, as a treatment for ALS. The gene discussed is HMGB1; the disease is amyotrophic lateral sclerosis.